Dianthus Therapeutics Inc Financials
This page shows Dianthus Therapeutics Inc (DNTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Dianthus Therapeutics Inc has an operating margin of -8739.3%, meaning the company retains $-8739 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -1633.7% the prior year.
Dianthus Therapeutics Inc's revenue declined 67.3% year-over-year, from $6.2M to $2.0M. This contraction results in a growth score of 0/100.
Dianthus Therapeutics Inc carries a low D/E ratio of 0.08, meaning only $0.08 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 13.32, Dianthus Therapeutics Inc holds $13.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Dianthus Therapeutics Inc generates a -32.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -24.1% the prior year.
Dianthus Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Dianthus Therapeutics Inc generates $0.80 in operating cash flow (-$129.1M OCF vs -$162.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Dianthus Therapeutics Inc generated $2.0M in revenue in fiscal year 2025. This represents a decrease of 67.3% from the prior year.
Dianthus Therapeutics Inc's EBITDA was -$177.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 74.7% from the prior year.
Dianthus Therapeutics Inc reported -$162.3M in net income in fiscal year 2025. This represents a decrease of 91.1% from the prior year.
Dianthus Therapeutics Inc earned $-4.20 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 64.7% from the prior year.
Cash & Balance Sheet
Dianthus Therapeutics Inc held $51.1M in cash against $0 in long-term debt as of fiscal year 2025.
Dianthus Therapeutics Inc paid $0.00 per share in dividends in fiscal year 2025.
Dianthus Therapeutics Inc had 43M shares outstanding in fiscal year 2025. This represents an increase of 38.9% from the prior year.
Margins & Returns
Dianthus Therapeutics Inc's operating margin was -8739.3% in fiscal year 2025, reflecting core business profitability. This is down 7105.6 percentage points from the prior year.
Dianthus Therapeutics Inc's net profit margin was -7973.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 6610.6 percentage points from the prior year.
Dianthus Therapeutics Inc's ROE was -32.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 8.8 percentage points from the prior year.
Capital Allocation
Dianthus Therapeutics Inc invested $145.6M in research and development in fiscal year 2025. This represents an increase of 75.2% from the prior year.
DNTH Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $284K-28.3% | $396K+105.2% | $193K-83.4% | $1.2M-12.3% | $1.3M-39.0% | $2.2M+16.6% | $1.9M+113.2% | $874K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $59.9M+84.4% | $32.5M+23.8% | $26.3M-2.8% | $27.0M+2.2% | $26.4M+3.4% | $25.5M+41.4% | $18.1M+38.2% | $13.1M |
| SG&A Expenses | $9.9M+21.2% | $8.2M-7.6% | $8.9M+20.9% | $7.3M+7.4% | $6.8M+4.6% | $6.5M+8.9% | $6.0M+6.3% | $5.6M |
| Operating Income | -$69.5M-72.6% | -$40.3M-15.3% | -$34.9M-5.3% | -$33.2M-4.0% | -$31.9M-6.7% | -$29.9M-34.7% | -$22.2M-24.4% | -$17.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$64.4M-75.3% | -$36.8M-16.2% | -$31.6M-7.2% | -$29.5M-3.8% | -$28.4M-13.0% | -$25.2M-43.0% | -$17.6M-28.1% | -$13.7M |
| EPS (Diluted) | N/A | $-0.97-10.2% | $-0.88-7.3% | $-0.82 | N/A | $-0.74-45.1% | $-0.51+5.6% | $-0.54 |
DNTH Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $530.9M-8.1% | $577.4M+77.1% | $326.1M-6.5% | $348.6M-6.8% | $374.0M+5.6% | $354.2M-4.0% | $369.0M-3.5% | $382.5M |
| Current Assets | $409.4M-1.1% | $413.8M+57.0% | $263.6M-2.7% | $271.0M-3.5% | $280.9M-2.3% | $287.5M-21.4% | $365.7M-4.0% | $380.9M |
| Cash & Equivalents | $51.1M-8.7% | $56.0M+322.9% | $13.2M+30.9% | $10.1M-55.6% | $22.8M-32.3% | $33.7M-89.3% | $314.2M-4.7% | $329.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $52K-99.0% | $5.0M+12720.5% | $39K-96.1% | $1.0M | $0-100.0% | $1.4M+65.5% | $840K+93.1% | $435K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $37.5M+21.1% | $31.0M+34.8% | $23.0M+15.1% | $20.0M-7.2% | $21.5M+31.7% | $16.4M+52.2% | $10.7M+9.9% | $9.8M |
| Current Liabilities | $30.7M+28.8% | $23.9M+18.7% | $20.1M+18.5% | $17.0M-8.1% | $18.5M+17.5% | $15.7M+56.6% | $10.0M+11.9% | $9.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $493.4M-9.7% | $546.5M+80.3% | $303.1M-7.8% | $328.6M-6.8% | $352.5M+4.3% | $337.9M-5.7% | $358.2M-3.9% | $372.7M |
| Retained Earnings | -$336.7M-23.7% | -$272.3M-15.6% | -$235.5M-15.5% | -$203.9M-16.9% | -$174.4M-19.5% | -$146.0M-20.8% | -$120.8M-17.1% | -$103.2M |
DNTH Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$47.0M-53.8% | -$30.6M-27.9% | -$23.9M+13.5% | -$27.6M-0.7% | -$27.4M-29.0% | -$21.3M-46.4% | -$14.5M+2.8% | -$14.9M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $37.2M+118.5% | -$201.3M-861.1% | $26.4M+78.8% | $14.8M+164.0% | -$23.1M+91.1% | -$259.4M-22286.8% | $1.2M+121.2% | -$5.5M |
| Financing Cash Flow | $4.9M-98.2% | $274.5M+48229.8% | $568K+252.8% | $161K-99.6% | $39.7M+13304.1% | $296K+113.5% | -$2.2M-101.0% | $217.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DNTH Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -24486.3%-14312.5pp | -10173.7%+7923.1pp | -18096.9%-15244.2pp | -2852.7%-445.8pp | -2406.9%-1030.3pp | -1376.6%-184.8pp | -1191.8%+849.8pp | -2041.6% |
| Net Margin | -22687.3%-13403.2pp | -9284.1%+7104.0pp | -16388.1%-13850.6pp | -2537.5%-392.7pp | -2144.8%-985.8pp | -1159.0%-213.9pp | -945.1%+627.9pp | -1573.0% |
| Return on Equity | -13.1%-6.3pp | -6.7%+3.7pp | -10.4%-1.5pp | -9.0%-0.9pp | -8.1%-0.6pp | -7.4%-2.5pp | -4.9%-1.2pp | -3.7% |
| Return on Assets | -12.1%-5.8pp | -6.4%+3.3pp | -9.7%-1.2pp | -8.5%-0.9pp | -7.6%-0.5pp | -7.1%-2.3pp | -4.8%-1.2pp | -3.6% |
| Current Ratio | 13.32-4.0 | 17.35+4.2 | 13.12-2.9 | 15.99+0.8 | 15.22-3.1 | 18.30-18.2 | 36.46-6.1 | 42.52 |
| Debt-to-Equity | 0.08+0.0 | 0.06-0.0 | 0.08+0.0 | 0.060.0 | 0.06+0.0 | 0.05+0.0 | 0.030.0 | 0.03 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Dianthus Therapeutics Inc's annual revenue?
Dianthus Therapeutics Inc (DNTH) reported $2.0M in total revenue for fiscal year 2025. This represents a -67.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Dianthus Therapeutics Inc's revenue growing?
Dianthus Therapeutics Inc (DNTH) revenue declined by 67.3% year-over-year, from $6.2M to $2.0M in fiscal year 2025.
Is Dianthus Therapeutics Inc profitable?
No, Dianthus Therapeutics Inc (DNTH) reported a net income of -$162.3M in fiscal year 2025, with a net profit margin of -7973.3%.
What is Dianthus Therapeutics Inc's EBITDA?
Dianthus Therapeutics Inc (DNTH) had EBITDA of -$177.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Dianthus Therapeutics Inc's operating margin?
Dianthus Therapeutics Inc (DNTH) had an operating margin of -8739.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Dianthus Therapeutics Inc's net profit margin?
Dianthus Therapeutics Inc (DNTH) had a net profit margin of -7973.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Dianthus Therapeutics Inc's return on equity (ROE)?
Dianthus Therapeutics Inc (DNTH) has a return on equity of -32.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Dianthus Therapeutics Inc's operating cash flow?
Dianthus Therapeutics Inc (DNTH) generated -$129.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Dianthus Therapeutics Inc's total assets?
Dianthus Therapeutics Inc (DNTH) had $530.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Dianthus Therapeutics Inc spend on research and development?
Dianthus Therapeutics Inc (DNTH) invested $145.6M in research and development during fiscal year 2025.
What is Dianthus Therapeutics Inc's current ratio?
Dianthus Therapeutics Inc (DNTH) had a current ratio of 13.32 as of fiscal year 2025, which is generally considered healthy.
What is Dianthus Therapeutics Inc's debt-to-equity ratio?
Dianthus Therapeutics Inc (DNTH) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Dianthus Therapeutics Inc's return on assets (ROA)?
Dianthus Therapeutics Inc (DNTH) had a return on assets of -30.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Dianthus Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Dianthus Therapeutics Inc (DNTH) had $51.1M in cash against an annual operating cash burn of $129.1M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Dianthus Therapeutics Inc's Piotroski F-Score?
Dianthus Therapeutics Inc (DNTH) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Dianthus Therapeutics Inc's earnings high quality?
Dianthus Therapeutics Inc (DNTH) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Dianthus Therapeutics Inc?
Dianthus Therapeutics Inc (DNTH) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.